Teva and Sanofi Share Positive Results from Phase II Study in Ulcerative Colitis and Crohn’s Disease
Duvakitug, a monoclonal antibody, demonstrated clinical remission and endoscopic response in the study, meeting its primary endpoints.
Teva and Sanofi have announced positive results from the Phase IIb RELIEVE UCCD study evaluating duvakitug (TEV’574/SAR447189), a human IgG1-λ2 monoclonal antibody targeting TL1A, for the treatment of moderate-to-severe inflammatory bowel disease (IBD). The study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn’s disease (CD).1
According to the results, 36.2% (low-dose) and 47.8% (high-dose) of patients with UC treated with duvakitug achieved clinical remission compared to just 20.45% in the placebo arm. In patients with CD, duvakitug once again achieved its primary endpoint—26.1% (low-dose) and 47.8% (high-dose) of patients achieved an endoscopic response compared to 13.0% on placebo.
In a press release, Eric Hughes, MD, PhD, head of global R&D and chief medical officer at Teva said, “The results from the RELIEVE UCCD study have exceeded our expectations, and I am deeply moved by the potential for duvakitug to help treat and meaningfully improve the quality of life of people living with IBD. These positive results reinforce Teva's ability to develop and accelerate access to innovative medicines. We are excited to collaborate on the next phase of development with our partner, Sanofi, and we would like to thank the investigators and patients who participated in this study.”
The Phase IIb RELIEVE UCCD trial is a 14-week randomized, double-blinded, dose-ranging study to determine the efficacy, safety, pharmacokinetics and tolerability of duvakitug in adults with moderate to severe UC or CD. Participants who completed the initial 14-week study were eligible to participate in a long-term extension study, which is currently ongoing. Responders from the 14-week study could enter a 44-week maintenance period to receive a low or high dose of duvakitug every four weeks. Non-responders could enter a 14-week re-induction period. Primary endpoints across both studies are clinical remission for the UC cohort and endoscopic response in the CD cohort.
“These unprecedented results show that duvakitug could represent the next frontier in treating ulcerative colitis and Crohn’s disease. If the magnitude of effect persists in the Phase III program, we believe we will have a differentiated medicine for IBD patients who are in urgent need of new options,” Houman Ashrafian, MD, PhD, executive vice president, head of R&D at Sanofi, said in the press release. “The duvakitug program and this partnership underscore Sanofi’s strategy of following the science to identify and rapidly advance breakthrough medicines for patients.”
Reference
1. Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease. News release. Teva. December 17, 2024. Accessed December 18, 2024. https://www.tevapharm.com/news-and-media/latest-news/teva-and-sanofi-announce-duvakitug-anti-tl1a-positive-phase-2b-results-demonstrating-best-in-class-pote/
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
